$KZR News
Last published 7mo ago
- 7mo agoAUPHKZRAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
- 8mo agoKZREnodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life SciencesBusiness WireTransaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia's novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company
- 12mo agoKZRKezar Life Sciences Reports Third Quarter 2025 Financial ResultsBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended
- 1y agoKZRKezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the
- 1y agoKZRKezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic AlternativesBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR, the Company)), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory
- 1y agoKZRKezar Life Sciences to Participate in Two Upcoming Investor ConferencesBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief
- 1y agoKZRKezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness WireAnnounced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis Submitted Type C meeting request to the FDA to meet during
- 1y agoKZRKezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of
- 1y agoKZRKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief
- 1y agoKZRKezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial ResultsBusiness WireCompany-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a
- 1y agoKZRKezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline
- 1y agoKZRKezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a
- 1y agoKZRKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness WireTopline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 Cash, cash equivalents and marketable securities totaled $148 million
- 2y agoKZRKezar Life Sciences Announces 1-for-10 Reverse Stock SplitBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a
- 2y agoKZRKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors
- 2y agoKZRKezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE UpdateBusiness WirePORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring Committee (IDMC); reiterating guidance of topline data in
- 2y agoKZRKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalBusiness WireKezar Life Sciences, Inc. ("Kezar" or the "Company") (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has
- 2y agoKZRKezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus NephritisBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference
- 2y agoKZRKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary cessation in enrollment of
- 2y agoKZRKezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder
- 2y agoKZRKezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness WireEnrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of zetomipzomib in
- 2y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the
- 2y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the
- 2y agoKZRKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk,
- 2y agoKZRKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness WirePALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in
- 2y agoKZRKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the
- 2y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
- 2y agoKZRKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateBusiness WirePALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in
- 2y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
- 2y agoKZRKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief
- 2y agoKZREverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisBusiness WireEverest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's
- 2y agoKZREverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisPR NewswireEverest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's...
- 2y agoKZRKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief
- 2y agoKZRKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateBusiness WireStrategic restructuring extends cash runway to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis Collaboration and license agreement with Everest Medicines to develop and
- 3y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
- 3y agoACHLADVMAVIRBOLT+610 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical
- 3y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
- 3y agoKZRKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerBusiness WireStrategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus
- 3y agoKZRKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaBusiness WirePartnership with Everest Medicines will address a critical unmet medical need for patients with active lupus nephritis in Asia Kezar is eligible to receive up to $132.5 million in total payments, as well as tiered
- 3y agoKZRKezar Life Sciences to Participate in Three Upcoming Investor ConferencesBusiness WireKezar Life Sciences, Inc.
- 3y agoKZRKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateBusiness WirePALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment KZR-261 dose
- 3y agoKZRKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc.,
- 3y agoKZRKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc.,
- 3y agoKZRKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc.,
- 3y agoKZRKezar Life Sciences to Participate in the Jefferies Healthcare ConferenceBusiness WireKezar Life Sciences, Inc.
- 3y agoKZRKezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness WirePALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis on track to initiate in first half of 2023 KZR-261 dose escalation study continues to progress; the dose expansion study expected to
- 3y agoKZRKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business WireKezar Life Sciences, Inc.,
- 3y agoKZRA Phase 2b Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) - NCT05781750ClinicalTrials.govTo evaluate the efficacy of zetomipzomib, To evaluate safety of zetomipzomib, Partial Renal Remission (PRR), CRR
- 3y agoKZRKezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateBusiness WirePALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis to initiate in first half of 2023 KZR-261 dose escalation study currently enrolling sixth cohort; the dose expansion study expected to
- 3y agoKZRKezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023Business WireKezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull